Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Blueprint Medicines receives CRL from FDA on NDA for avapritinib » 08:02
05/15/20
05/15
08:02
05/15/20
08:02
BPMC

Blueprint Medicines

$64.22 /

+0.41 (+0.64%)

Blueprint Medicines…

Blueprint Medicines announced that the U.S. FDA has issued a complete response letter for the new drug application of avapritinib for the treatment of adults with unresectable or metastatic fourth-line gastrointestinal stromal tumor. The CRL states that the FDA cannot approve the application.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$64.22 /

+0.41 (+0.64%)

BPMC Blueprint Medicines
$64.22 /

+0.41 (+0.64%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
BPMC Blueprint Medicines
$64.22 /

+0.41 (+0.64%)

BPMC Blueprint Medicines
$64.22 /

+0.41 (+0.64%)

Conference/Events
FDA PDUFA Date for Blueprint Medicines Avapritinib is May 14, 2020  07:50
05/14/20
05/14
07:50
05/14/20
07:50
BPMC

Blueprint Medicines

$63.81 /

+0.53 (+0.84%)

 
ShowHide Related Items >><<
BPMC Blueprint Medicines
$63.81 /

+0.53 (+0.84%)

BPMC Blueprint Medicines
$63.81 /

+0.53 (+0.84%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet
05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
BPMC Blueprint Medicines
$63.81 /

+0.53 (+0.84%)

BPMC Blueprint Medicines
$63.81 /

+0.53 (+0.84%)

Downgrade
Deciphera downgraded to Neutral on GIST program risks at Nomura Instinet » 16:06
05/06/20
05/06
16:06
05/06/20
16:06
DCPH

Deciphera

$55.67 /

-1.38 (-2.42%)

, BPMC

Blueprint Medicines

$59.05 /

-0.81 (-1.35%)

As previously reported,…

As previously reported, Nomura Instinet analyst Christopher Marai downgraded Deciphera (DCPH) to Neutral from Buy with a price target of $60, down from $84. Despite Blueprint Medicines' (BPMC) recent avapritinib failure in the VOYAGER trial, Deciphera's GIST program faces "mounting risky events," including a commercial launch in a potentially narrow setting, which Marai sees putting downward pressure on Deciphera shares in the near-term. While he sees little risk to ripretinib's approval, Marai views the "show-me" launch as a risk to upside, the analyst added.

ShowHide Related Items >><<
DCPH Deciphera
$55.67 /

-1.38 (-2.42%)

05/06/20 Nomura Instinet
Deciphera downgraded to Neutral from Buy at Nomura Instinet
05/06/20 H.C. Wainwright
Deciphera price target raised to $80 from $60 at H.C. Wainwright
05/05/20 Piper Sandler
Impact of COVID-19 on Deciphera minimal, says Piper Sandler
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
BPMC Blueprint Medicines
$59.05 /

-0.81 (-1.35%)

05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
Hot Stocks
Blueprint Medicines: Cash sufficient to fund operating expenses to 2H22 » 07:14
05/06/20
05/06
07:14
05/06/20
07:14
BPMC

Blueprint Medicines

$59.86 /

+1.72 (+2.96%)

Based on its current…

Based on its current operating plans, Blueprint Medicines expects that its existing cash, cash equivalents and investments, together with anticipated product revenues but excluding any potential option fees, milestone payments or other payments under its collaboration or license agreements, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements into the second half of 2022.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$59.86 /

+1.72 (+2.96%)

05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
Earnings
Blueprint Medicines reports Q1 EPS ($2.11), consensus ($2.17) » 07:13
05/06/20
05/06
07:13
05/06/20
07:13
BPMC

Blueprint Medicines

$59.86 /

+1.72 (+2.96%)

Reports Q1 revenue $6.2M,…

Reports Q1 revenue $6.2M, consensus $5.44M.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$59.86 /

+1.72 (+2.96%)

05/05/20 Barclays
Blueprint Medicines initiated with an Equal Weight at Barclays
04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
Initiation
Blueprint Medicines initiated with an Equal Weight at Barclays » 06:22
05/05/20
05/05
06:22
05/05/20
06:22
BPMC

Blueprint Medicines

$58.14 /

+1.11 (+1.95%)

Barclays analyst Peter…

Barclays analyst Peter Lawson initiated coverage of Blueprint Medicines with an Equal Weight rating and $59 price target. The analyst expanded coverage with six additional SMID cap oncology stocks in the U.S. Small & Mid Cap Biotechnology sector, where he has a Positive view. Lawson is awaiting more data from Blueprint before getting more constructive on the shares.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$58.14 /

+1.11 (+1.95%)

04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
04/28/20 JonesTrading
JonesTrading sees Deciphera as takeover target after Blueprint study miss
Recommendations
Deciphera price target raised to $55 from $50 at SVB Leerink » 08:10
04/29/20
04/29
08:10
04/29/20
08:10
DCPH

Deciphera

$56.12 /

+7.92 (+16.43%)

, BPMC

Blueprint Medicines

$58.63 /

-12.21 (-17.24%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens raised the firm's price target on Deciphera (DCPH) to $55 from $50 and keeps a Market Perform rating on the shares. Following Blueprint Medicines (BPMC) Ayvakit's demise, Deciphera's ripretinib remains the only next-generation drug to treat KIT driven GIST, the analyst notes. Therefore, he believes the drug could capture about $1.6B aggregate revenues in U.S. and EU. Nonetheless, Berens points out that if INTRIGUE fails, then ripretinib revenues will be significantly impacted, decreasing from $1.6B to about $590M, which would impact his valuation of the company by over 50%.

ShowHide Related Items >><<
DCPH Deciphera
$56.12 /

+7.92 (+16.43%)

04/28/20 JonesTrading
JonesTrading sees Deciphera as takeover target after Blueprint study miss
03/04/20 Barclays
Barclays starts small, mid cap Biotechnology sector with Positive view
03/04/20 Barclays
Deciphera initiated with an Overweight at Barclays
02/24/20 Jefferies
Epizyme, Blueprint among cancer companies that fit M&A criteria, says Jefferies
BPMC Blueprint Medicines
$58.63 /

-12.21 (-17.24%)

04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
04/01/20 Piper Sandler
Piper Sandler prefers to stay on sidelines after Blueprint Medicines update
Recommendations
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink » 07:54
04/29/20
04/29
07:54
04/29/20
07:54
BPMC

Blueprint Medicines

$58.63 /

-12.21 (-17.24%)

SVB Leerink analyst…

SVB Leerink analyst Andrew Berens lowered the firm's price target on Blueprint Medicines to $105 from $125 following the company's VOYAGER trial failure and given Blueprint Medicines management's comments that they will not be pursuing KIT GIST. The analyst keeps an Outperform rating on the shares.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$58.63 /

-12.21 (-17.24%)

04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
04/28/20 JonesTrading
JonesTrading sees Deciphera as takeover target after Blueprint study miss
04/01/20 Piper Sandler
Piper Sandler prefers to stay on sidelines after Blueprint Medicines update
03/24/20 Wedbush
Blueprint Medicines added to Best Ideas List at Wedbush
Recommendations
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright » 07:14
04/29/20
04/29
07:14
04/29/20
07:14
BPMC

Blueprint Medicines

$58.63 /

-12.21 (-17.24%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Andrew Fein lowered the firm's price target on Blueprint Medicines to $66 from $100 and reiterates a Buy rating on the shares. The Voyager topline miss denies the possibility of third-line and fourth-line approvals, and the clinical utility of avapritinib in gastrointestinal stromal tumor is now likely limited to a small subset of patients with PDGFR-alpha mutations, Fein tells investors in a research note. The analyst, however, believes the fundamentals of Blueprint "remain strong."

ShowHide Related Items >><<
BPMC Blueprint Medicines
$58.63 /

-12.21 (-17.24%)

04/28/20 JonesTrading
JonesTrading sees Deciphera as takeover target after Blueprint study miss
04/01/20 Piper Sandler
Piper Sandler prefers to stay on sidelines after Blueprint Medicines update
03/24/20 Wedbush
Blueprint Medicines added to Best Ideas List at Wedbush
03/17/20 SVB Leerink
Blueprint Medicines price target raised to $125 from $116 at SVB Leerink
On The Fly
Fly Intel: Wall Street's top stories for Tuesday » 16:48
04/28/20
04/28
16:48
04/28/20
16:48
BA

Boeing

$130.82 /

+2.31 (+1.80%)

, MMM

3M

$157.61 /

+3.945 (+2.57%)

, CAT

Caterpillar

$115.39 /

+0.11 (+0.10%)

, UPS

UPS

$96.48 /

-6.09 (-5.94%)

, MRK

Merck

$81.18 /

-2.8 (-3.33%)

, PFE

Pfizer

$37.91 /

-0.38 (-0.99%)

, PEP

PepsiCo

$136.30 /

+1.82 (+1.35%)

, MNST

Monster Beverage

$60.13 /

-0.41 (-0.68%)

, TSN

Tyson Foods

$62.78 /

+3.1 (+5.19%)

, CAG

Conagra Brands

$34.62 /

+0.03 (+0.09%)

, PPC

Pilgrim's Pride

$21.34 /

+0.83 (+4.05%)

, SAFM

Sanderson Farms

$136.52 /

-3.48 (-2.49%)

, HRL

Hormel Foods

$47.75 /

+1.14 (+2.45%)

, SNDX

Syndax

$19.56 /

+8.09 (+70.53%)

, FFIV

F5 Networks

$140.95 /

+10 (+7.64%)

, CGNX

Cognex

$55.86 /

+5.955 (+11.93%)

, BPMC

Blueprint Medicines

$58.63 /

-12.21 (-17.24%)

, HLIT

Harmonic

$5.65 /

-0.88 (-13.48%)

, LRN

K12

$22.01 /

-3.12 (-12.42%)

The major averages were…

Open Full Text

ShowHide Related Items >><<
BA Boeing
$130.82 /

+2.31 (+1.80%)

04/28/20 Credit Suisse
Embraer downgraded to Underperform from Neutral at Credit Suisse
04/20/20
Fly Intel: Top five analyst downgrades
04/20/20 Citi
Citi downgrades Boeing to Neutral on 'collapsed' aerospace story
04/20/20 Citi
Boeing downgraded to Neutral from Buy at Citi
MMM 3M
$157.61 /

+3.945 (+2.57%)

04/29/20 Credit Suisse
3M price target raised to $180 from $165 at Credit Suisse
04/29/20 RBC Capital
3M price target raised to $148 from $143 at RBC Capital
03/30/20
Fly Intel: Top five analyst downgrades
03/30/20 Gordon Haskett
3M downgraded to Underperform from Hold at Gordon Haskett
CAT Caterpillar
$115.39 /

+0.11 (+0.10%)

04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Morgan Stanley
Caterpillar downgraded to Underweight on construction risks at Morgan Stanley
04/27/20 Morgan Stanley
Caterpillar downgraded to Underweight from Equal Weight at Morgan Stanley
04/13/20
Fly Intel: Top five analyst downgrades
UPS UPS
$96.48 /

-6.09 (-5.94%)

04/29/20
Fly Intel: Top five analyst downgrades
04/29/20 Wells Fargo
UPS price target lowered to $111 from $121 at Wells Fargo
04/29/20 BMO Capital
UPS downgraded to Underperform from Market Perform at BMO Capital
04/28/20 Roth Capital
Workhorse Group initiated with a Buy at Roth Capital
MRK Merck
$81.18 /

-2.8 (-3.33%)

04/27/20 SVB Leerink
Clovis downgraded to Underperform at SVB Leerink as prostate opportunity fades
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/23/20 Mizuho
Merck business disruptions have been modest, says Mizuho
03/02/20 William Blair
Merck results revive fears about Seattle Genetics' Adcetris, says William Blair
PFE Pfizer
$37.91 /

-0.38 (-0.99%)

04/28/20 SVB Leerink
SVB Leerink bullish on Zentalis, initiates with an Outperform
04/28/20 BofA
BioNTech downgraded to Neutral from Buy at BofA
04/03/20 Canaccord
BioNTech price target raised to $60 from $22 at Canaccord
03/25/20 Piper Sandler
Piper Sandler sees FY20 U.S. sales of Opko's Rayaldee at $52.5M
PEP PepsiCo
$136.30 /

+1.82 (+1.35%)

04/29/20 Guggenheim
PepsiCo price target raised to $145 from $134 at Guggenheim
04/29/20 Cowen
PepsiCo price target raised to $156 from $135 at Cowen
04/20/20 Morgan Stanley
Campbell Soup initiated with an Equal Weight at Morgan Stanley
04/01/20 Goldman Sachs
PepsiCo resumed a Conviction Buy at Goldman Sachs
MNST Monster Beverage
$60.13 /

-0.41 (-0.68%)

04/16/20
Fly Intel: Top five analyst initiations
04/16/20 BofA
Monster Beverage reinstated with a Buy at BofA
04/01/20 Goldman Sachs
Monster Beverage resumed with a Buy at Goldman Sachs
TSN Tyson Foods
$62.78 /

+3.1 (+5.19%)

04/29/20 Piper Sandler
Tyson Foods downgraded to Neutral on foodservice risk at Piper Sandler
04/28/20 Piper Sandler
Tyson Foods downgraded to Neutral from Overweight at Piper Sandler
04/24/20
Fly Intel: Top five analyst downgrades
CAG Conagra Brands
$34.62 /

+0.03 (+0.09%)

03/18/20 Bernstein
Conagra Brands upgraded to Market Perform from Underperform at Bernstein
02/27/20 Standpoint Research
Conagra Brands upgraded to Buy from Hold at Standpoint Research
02/17/20 Stifel
Conagra long-term thesis intact despite reduced outlook, says Stifel
01/23/20
Fly Intel: Top analyst initiations
PPC Pilgrim's Pride
$21.34 /

+0.83 (+4.05%)

03/31/20 Barclays
Beyond Meat price target lowered to $100 from $130 at Barclays
02/24/20 Goldman Sachs
Pilgrim's Pride price target lowered to $27 from $30 at Goldman Sachs
01/16/20 Stephens
Pilgrim's Pride downgraded to Equal Weight from Overweight at Stephens
11/14/19 BofA
Sanderson Farms upgraded to Buy from Underperform at BofA/Merrill
SAFM Sanderson Farms
$136.52 /

-3.48 (-2.49%)

04/03/20 Credit Suisse
Sanderson Farms price target lowered to $135 from $160 at Credit Suisse
04/02/20
Fly Intel: Top five analyst downgrades
04/02/20 BofA
Sanderson Farms downgraded to Neutral from Buy at BofA
03/31/20 Barclays
Sanderson upgraded to Overweight with $168 price target at Barclays
HRL Hormel Foods
$47.75 /

+1.14 (+2.45%)

04/29/20 Piper Sandler
Hormel downgraded to Neutral on foodservice risk at Piper Sandler
04/28/20 Piper Sandler
Hormel Foods downgraded to Neutral from Overweight at Piper Sandler
03/26/20
Fly Intel: Top five analyst upgrades
SNDX Syndax
$19.56 /

+8.09 (+70.53%)

04/28/20 Baird
Syndax price target raised to $33 from $27 at Baird
04/21/20 H.C. Wainwright
Syndax's SNDX-5613 granted orphan drug designation, says H.C. Wainwright
03/23/20 Citi
Sarepta, DBV among Citi's SMid Biotech picks amid coronavirus outbreak
03/12/20 Citi
Syndax price target raised to $18 from $12 at Citi
FFIV F5 Networks
$140.95 /

+10 (+7.64%)

04/28/20 Needham
F5 Networks price target raised to $170 from $140 at Needham
04/28/20 MKM Partners
F5 Networks price target raised to $152 from $144 at MKM Partners
04/28/20 RBC Capital
F5 Networks price target raised to $135 from $115 at RBC Capital
04/28/20 Goldman Sachs
F5 Networks upgraded to Neutral from Sell at Goldman Sachs
CGNX Cognex
$55.86 /

+5.955 (+11.93%)

04/28/20 Raymond James
Cognex price target raised to $60 from $48 at Raymond James
03/23/20 Morgan Stanley
Morgan Stanley cuts Multi-Industry estimates, shakes up ratings with 7 changes
03/23/20 Morgan Stanley
Cognex downgraded to Underweight from Equal Weight at Morgan Stanley
12/12/19 UBS
Cognex initiated with a Neutral at UBS
BPMC Blueprint Medicines
$58.63 /

-12.21 (-17.24%)

04/29/20 SVB Leerink
Deciphera price target raised to $55 from $50 at SVB Leerink
04/29/20 SVB Leerink
Blueprint Medicines price target lowered to $105 from $125 at SVB Leerink
04/29/20 H.C. Wainwright
Blueprint Medicines price target lowered to $66 from $100 at H.C. Wainwright
04/28/20 JonesTrading
JonesTrading sees Deciphera as takeover target after Blueprint study miss
HLIT Harmonic
$5.65 /

-0.88 (-13.48%)

04/14/20 JPMorgan
Harmonic initiated with an Overweight at JPMorgan
07/10/19 Stifel
Harmonic price target raised to $10 from $7 at Stifel
06/14/19
Fly Intel: Top five analyst upgrades
06/14/19 Raymond James
Harmonic upgraded to Outperform after multi-year transition at Raymond James
LRN K12
$22.01 /

-3.12 (-12.42%)

01/28/20 Barrington
K12 price target lowered to $30 from $40 at Barrington
01/28/20 BMO Capital
K12 price target lowered to $23 from $27 at BMO Capital
08/13/19 William Blair
William Blair starts Chegg, K12 with Outperform ratings
08/12/19 William Blair
K12 initiated with an Outperform at William Blair

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.